Adverse events in children and adolescents in tuberculosis chemotherapy with second- and third-line drugs

The purpose of the study. analysis of undesirable side effects when using second-and third-line drugs in the chemotherapy regimens of tuberculosis in children and adolescents. Materials and methods. The study included 109 children with newly diagnosed tuberculosis at the age of 0 to 18 years, who received b ckup drugs. Group I consisted of patients receiving fluoroquinolones and second – line oral bacteriostatic drugs along with first – line drugs (71 people, 65.1%), group II-patients who, in addition to second-line drugs, included linezolid in the chemotherapy regimen (28 people, 25.7%), group III-patients whose treatment regimen included bedaquiline, linezolid and PASC (10 people, 9.2%). The results of the study. The development of undesirable side effects in the three groups of patients was noted in 32.4–42.8%, which did not differ significantly. Most of them were toxic reactions (from 100.0% to 69.2%). Undesirable side effects in the regimens including linezolid were observed only in group III, in 20% (2 people) with severe concomitant pathology. In group II, where linezolid was used without bedaquiline, no adverse reactions to linezolid were observed. Conclusions. The administration of PTP to children from group A according to WHO (levofloxacin / moxifloxacin linezolid, bedaquiline) in some cases is vital, since only they can provide an adequate chemotherapy regimen. There was no significant increase in the number and severity of adverse events.